Global End Stage Renal Disease Market Report, Industry Analysis and Forecast to 2029

Market Size and Forecast (2025–2035)

The end-stage renal disease (ESRD) market is projected to grow steadily over the forecast period, starting from approximately USD 40.88 billion in 2025 and reaching USD 67.36 billion by 2035, driven by a compound annual growth rate (CAGR) of 5.12%. This growth is attributed to the increasing prevalence of chronic kidney disease (CKD) progressing to ESRD and advancements in treatment options.

To illustrate the year-over-year growth, the following table presents projected market values, calculated based on the specified CAGR applied progressively from the 2025 base value:

Note: Values are rounded to two decimal places and derived from annual compounding at 5.12%.

Market Share by Segments

The ESRD market is segmented by treatment type and other categories. Dialysis dominates due to its widespread use as a life-sustaining therapy, while transplantation offers a more permanent solution but is limited by organ availability. Within dialysis, hemodialysis is the most common modality.

The following table summarizes estimated market shares by key segments (based on recent industry data, projected trends toward 2035):

These shares reflect the prominence of dialysis, particularly hemodialysis, in managing ESRD, with a growing shift toward home-based options.

Trends

Key trends shaping the ESRD market include:

• Shift to Home-Based and Patient-Centric Care: Increasing adoption of home dialysis and remote monitoring to improve quality of life and reduce costs.
• Technological Innovations: Development of wearable artificial kidneys, high-flux dialyzers, and artificial kidney research.
• Focus on Conservative Management: Growing use of non-dialysis options for patients opting out of invasive treatments.
• Integration of Advanced Therapies: Rising use of antidiabetic drugs like SGLT2 inhibitors to slow progression and emerging gene therapies.
• Market Consolidation: Mergers, acquisitions, and partnerships to enhance technology portfolios.

Growth Drivers

The market's expansion is fueled by several key drivers:

• Rising Prevalence of Risk Factors: Increasing cases of diabetes, hypertension, and CKD leading to ESRD.
• Aging Population: Demographic shifts contributing to higher ESRD incidence.
• Technological Advancements: Innovations in dialysis equipment and wearable devices improving treatment efficacy.
• Government Support and Reimbursement: Funding for infrastructure and favorable policies enhancing access to care.
• Awareness Initiatives: Programs raising awareness about kidney health and early intervention.

Key Players

The competitive landscape features major players emphasizing R&D, product innovation, and strategic collaborations. Prominent companies include:

• Fresenius Medical Care AG & Co. KGaA
• Baxter International Inc.
• Medtronic PLC
• B. Braun SE
• Nipro Corporation
• Asahi Kasei Medical Co., Ltd.
• Nikkiso Co., Ltd.
• BD (Becton, Dickinson and Company)
• Cantel Medical
• JMS Co. Ltd.

These firms dominate through advancements in dialysis technologies and expansions in home care solutions.

Strategic Analysis

Strategically, the ESRD market focuses on optimizing the value chain from device manufacturing to patient care delivery, with emphasis on cost-effective home therapies and digital integration for monitoring. Opportunities include R&D in regenerative medicine like xenotransplantation and artificial organs, as well as biosimilar drugs for cost reduction. Competitive strategies involve acquisitions to bolster portfolios and pricing models for emerging markets. Challenges such as high treatment costs and organ shortages persist, but growth in conservative and home-based options offers long-term potential.